176 results about "Immunopotency" patented technology

The invention belongs to the technical field of preparation of probiotics, and provides a bacterial strain with anti-allergic and immunity-improving effects and application of the bacterial strain. According to the method, a three-layer physical self-assembly structure is adopted, and polysaccharide-polyphenol layer-by-layer self-assembly coating treatment, lipid insertion layer treatment and calcium ion crosslinking protection coating treatment are sequentially carried out. And mannan oligosaccharide MOS and / or galactooligosaccharide GOS are / is mixed in the chitosan layer in a ratio of 0.05-0.15% w / v, and the surface sugar ligand density reaches 4-8 [mu] g per 10 CFU. The coating is constructed under the condition that the pH value is 5.4-5.8; the thickness of the lipid layer is 20-80 nm when the pH value is 5.6-6.2; the cross-linked layer is treated at the pH of 6.0-6.5, so that the gastric acid environment is stable for 2 hours, and the gastric acid is controllably released in intestinal juice for 2-4 hours. The prepared strain has the total thickness of 220-900 nm, the outermost layer coverage rate is larger than or equal to 85%, the gastric juice survival rate is remarkably improved, the strain can be prepared into an oral preparation to be used for preventing and relieving allergic diseases, the viable count of each dose is 1 * 10 <-1 > * 10 <-1 > CFU, and the process is mild and suitable for industrial production.

Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds or infections of the eye. In some embodiments, immunogenic ocular formulations disclosed herein include combinations of agents for prolonged exposure to the eye for improved outcomes.

The invention provides a probiotic composition for improving immunity and a preparation method thereof, and belongs to the technical field of probiotics. The preparation method comprises the following steps: fermenting selenium-enriched nostoc sphaeroides through selenium-enriched saccharomycetes to extract selenium-enriched nostoc sphaeroides polysaccharide and selenium-enriched nostoc sphaeroides protein peptide, mixing with traditional Chinese medicine polysaccharide obtained by extracting astragalus membranaceus, rhodiola rosea, codonopsis pilosula and pseudo-ginseng, and reacting with ferric salt to prepare a polysaccharide-Fe / selenium compound; solid residues are mixed and fermented, and active protein peptide is prepared from the solid residues and selenium-rich nostoc sphaeroides protein peptide; the probiotic composition capable of improving immunity is prepared by extracting a polysaccharide-Fe / selenium compound and a polysaccharide-Fe / selenium compound through an organic solvent, extracting a permeate through an organic solvent to obtain an active component, collecting a bacterial liquid, mixing and embedding the bacterial liquid in the polysaccharide-Fe / selenium compound and sodium alginate, and uniformly mixing the bacterial liquid with the active protein peptide, the active component, taurine and ginsenoside Rg3, so that the probiotic composition capable of improving immunity can play good anti-inflammatory, anti-oxidation, immunoregulation, anti-tumor, anti-virus and other roles, and has a good application prospect. Wide application prospects are realized.

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

The invention relates to the technical field of bioengineering, in particular to a preparation method of a probiotic and exosome preparation applied to immunoregulation. The probiotics and the umbilical cord stem cell exosome are combined for use, the immune regulation effect is enhanced from multiple targets and multiple ways, the immune function of the body is improved, the exosome carries a specific molecular marker and acts on immune cells in a targeted mode, precise immune regulation is achieved, and the preparation is in an oral form and convenient to use; the exosome is extracted from umbilical cord stem cells, has no pathogenicity and immunogenicity, and is low in adverse reaction risk after being used for a long time, and the prepared combined preparation can be used for treating and preventing various immune-related diseases, and also can be used for daily conditioning of people with low immunity and improving the body resistance; meanwhile, the combined preparation adopts micro-capsule embedding, so that the probiotics can be effectively protected from gastric acid and bile erosion, the survival rate and colonization efficiency of the probiotics in intestinal tracts are improved, the immunoregulation effect is further enhanced, and the combined preparation is convenient to store and transport and has a good application prospect.

The present invention involves an engineered probiotic bacterium comprising a heterologous nucleic acid, where the heterologous nucleic acid comprises a nucleic acid sequence encoding an anti-spike glycoprotein nanobody of a coronavirus. In one embodiment, the bacterium is Escherichia coli Nissle 1917. In another embodiment, the anti-spike glycoprotein nanobody appears on the surface of the probiotic bacteria.

This invention belongs to the field of plant extract technology, specifically relating to a plant extract composition for enhancing immunity. By weight, it is composed of the following raw materials: 3-5 parts Astragalus membranaceus extract, 2.5-4 parts Echinacea purpurea extract, and 1.5-3.5 parts Rhodiola rosea extract. This plant extract composition, through the scientific formulation of Astragalus membranaceus, Echinacea purpurea, and Rhodiola rosea, and an enzymatic extraction process, enhances the immunomodulatory effect. The combination of the three extracts increases the secretion of TNF-α and IL-6 by macrophages. Furthermore, the spleen lymphocyte stimulation index (SI) of the three extracts reaches 5.57, and the lymphocyte transformation rate increases from 191% to 457%. These results indicate that this plant extract composition effectively enhances the body's non-specific and cellular immune functions by activating macrophages and promoting T lymphocyte proliferation through multiple pathways, providing more comprehensive immune protection.

Lung cancer remains the leading cause of cancer-related deaths in the world. Despite the fact that introduction of immune checkpoint inhibitors (ICIs) led to a major advancement in lung cancer treatment, disease prognosis continues to remain low and a significant proportion of patients do not respond to such therapies. Cancer vaccines could potentially provide a complementary approach to boost antitumor immunity and act synergistically with ICIs. Novel tumor antigens shared by a large proportion of lung tumor cells are described herein. Several of the tumor antigens described herein derive from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these tumor antigens are described. The use of the tumor antigens, nucleic acids, compositions, cells and vaccines for the treatment of lung cancer is also described.

The invention discloses a composition for improving immunity and delaying senescence and a preparation method thereof. Belongs to the technical field of functional health. The composition comprises the following components in parts by mass: 5-50 parts of collagen, 10-80 parts of paeonia ostii tea, 1-20 parts of an antioxidant, 3-10 parts of an intestinal microecology regulator and 1-3 parts of an energy metabolism and nerve regulator. According to the invention, through multi-system cooperation and multi-target intervention, dual effects of immune enhancement and senescence delay are realized. Through scientific compounding and a special process, the product has the advantages of stable components, uniform activity and good solubility. Animal experiments and theoretical models show that immune organs can be effectively protected, accumulation of aging markers is reduced, and a solution is provided for development of comprehensive anti-aging health products.

Pharmaceutical compositions and therapeutic methods are provided comprising a single-domain antibody consisting of SEQ ID NO:1 and a pharmaceutically acceptable carrier. The antibody inhibits KRAS GTPase activity and inhibits phosphorylation of STAT3. In certain embodiments, inhibition of KRAS results in decreased phosphorylation of ERK1 / 2. The antibody reduces tumor cell surface PD-L1 expression and reduces VEGF production. The antibody crosses the blood-brain barrier following systemic administration and may exhibit sustained biological activity in vivo. Methods are provided for treating KRAS-mutant cancers, including pancreatic cancer and triple negative breast cancer, and for enhancing anti-tumor immunity through reduction of PD-L1 expression.

Peptides for use in systems that prevent the interaction of the FadA protein released from the Fusobacterium nucleatum (F. nucleatum) bacterium with E-cadherin, which has a carcinogenic effect, or the inhibition of the microorganism with antimicrobial agents and that will inhibit the carcinogenesis mechanisms of F. nucleatum infection and enable the development of therapeutic systems against infections that may occur due to the decreased immunity of patients undergoing cancer treatment with the use of peptides with anti-cancer and antimicrobial properties by developing ten peptides with FadA protein binding energy greater than −11.6 kcal / mol. Peptides with anticancer and antimicrobial properties allow the development of therapeutic systems to prevent F. nucleatum infection, to prevent cancer development after F. nucleatum infection, or to develop therapeutic systems against infections that occur due to the decreased immunity of cancer patients due to cancer treatment.

The present disclosure relates to a BCG based therapeutic agent using a BCG strain that overexpresses the STING agonist, c-di-AMP. This BCG strain, called BCG-disA-OE, enhances the elevated trained immunity of macrophages and promotes early anti-viral Type I interferon responses in a subject, providing protection against viral infections such as primary respiratory infections and SARS-CoV-2 infection.

This invention provides an oyster peptide and its application in enhancing immunity. The oyster peptide has a novel amino acid structure. The oyster peptide can enhance the activity of immune cells, promote the proliferation of immune cells, promote the development and maturation of immune organs, regulate the in vivo immune environment, promote the secretion of immunoglobulins, and improve humoral immunity.

The present application provides a kind of bioactive seventeen peptides and its application, belong to bioactive peptide technical field, the amino acid sequence of the seventeen peptides is as shown in SEQ ID NO.1;Seventeen peptides provided by the present application can significantly reduce immune damage, improve immune organ index, reduce spleen tissue damage, can significantly promote the secretion level of immunoglobulin and cytokine in blood;The polypeptide has immunoregulation, can improve immunity, can be used for preparing the product of enhancing immunity.

The invention belongs to the technical field of microbial preparations, and particularly relates to a compound fermentation composition for regulating animal immunity and a preparation method and application thereof. The composition is prepared from the following components in parts by weight: 1 to 10 parts of lactobacillus plantarum polysaccharide, 1 to 5 parts of clostridium butyricum, 0.5 to 2 parts of bifidobacterium, 0.5 to 5 parts of beta-glucan, 50 to 70 parts of corn starch and 0.1 to 1 part of silicon dioxide. The lactobacillus plantarum polysaccharide prepared by a specific preparation process, the clostridium butyricum, the bifidobacterium, the beta-glucan, the corn starch and the silicon dioxide are scientifically matched in a specific amount ratio range, so that the synergistic interaction effect of the immunoregulation component, the intestinal micro-ecological regulation component and other functional components is realized; according to the present invention, the IgA content in animal serum can be significantly increased so as to achieve high efficiency and long-term immunoregulation, the maximization of the utilization of each component is achieved, and the safe and effective bioactive substance is finally provided for the improvement of animal immunity.

The present invention relates to a novel Latilactobacillus curvatus strain WiKim0169 having immunoenhancing efficacy, and an immunoenhancing composition comprising same. In the present invention, it was found that the Latilactobacillus curvatus strain WiKim0169, which is a novel kimchi-derived strain, significantly increases splenic NK cell activity and increases the production of inflammatory mediators, immunoglobulins, and cytokines, thereby alleviating immunosuppressive responses. In addition, it was confirmed that the Latilactobacillus curvatus strain WiKim0169 has an effect of alleviating immune dysfunction by increasing the mRNA expression levels of iNOS, COX2, TNF-α, IL-1β, IL-6, IL-2, IL-12, and IL-10 in splenic tissue and increasing the phosphorylation levels of NF-κB and IκBα. Therefore, according to the present invention, the composition comprising the Latilactobacillus curvatus strain WiKim0169, which is a novel kimchi-derived strain, as an active ingredient is expected to be usefully employed as a pharmaceutical and functional food composition for immunoenhancement.

The invention provides application of M1 protein related substances in preparation of medicines for treating diseases caused by avian influenza viruses. The application is any one of the following applications: application of Y1 in preparation of medicines for preventing and / or treating diseases caused by avian influenza viruses or avian influenza virus infection; the Y2 is applied to preparation of an avian influenza virus inhibitor; the invention discloses application of Y3 in inhibition of avian influenza virus replication. After a mouse is immunized by the M1 recombinant protein, immune factors related to T cells are increased, secretion of proinflammatory factors is reduced, preparation is made for protecting a body from virus attack, and the M1 recombinant protein is also an expression for laterally improving the immunity of a host. The M1 protein has a good immune effect as an immunogen. The invention has application value in treatment of avian influenza virus and similar viruses.

The use of FcγRIIB as a mammalian mammary IgG transport receptor. By constructing FcγRIIB-knockout mice and FcγRIIB-knockout pigs, it is found that the ratio of serum and milk IgG concentrations of the FcγRIIB-knockout mice is significantly increased, that is, the relative concentration of milk IgG is reduced; and the FcγRIIB-knockout pigs have a significantly increased serum IgG content, but IgG is nearly undetectable in colostrum. Therefore, it has been proved for the first time that FcγRIIB is a receptor that mediates the trans-mammary transport of serum IgG to milk, and answers a long-term unsolved problem in the field of maternal passive immunity research. Furthermore, a new strategy is provided for increasing the IgG content of colostrum, thereby improving the early immunity and survival rate of neonatal domestic animals.

The invention discloses ginseng polysaccharide GP40030-1 as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The ginseng polysaccharide GP40030-1 provided by the invention can obviously promote the proliferation of mouse macrophages RAW264.7 and effectively improve the phagocytic ability of cells, is dose-dependent in a concentration range of 12.5-100 mu g / mL, shows excellent immunomodulatory activity, and has a wide application prospect in the aspect of preparing medicines, functional foods or health products for enhancing immunity.

The invention belongs to the technical field of cosmetics, and particularly relates to a composition with a skin protection effect and application thereof. Specifically, the invention provides the composition with skin protection effects of resisting blue light, improving skin immunity, regulating skin mood pressure and the like for the first time, the composition comprises supernate of animal bifidobacterium W3 fermentation liquor and porphyra haitanensis extract, and the supernate and the porphyra haitanensis extract have a synergistic effect. The composition has the effects of resisting blue light, improving skin immunity and regulating skin mood pressure by recovering the cell viability level under blue light damage, increasing the expression quantity of VDR mRNA in skin, increasing the expression quantity of mRNA of antibacterial peptide LL-37 and increasing the content of beta-enorphin, and has good practical application value.

Provided is a method for determining whether immune cells extracted from a patient have acquired immunity against tumor cells, which can reliably determine whether immune cells extracted from a patient have acquired immunity against tumor cells. [Solution] A method for determining whether immune cells have acquired immunity against tumor cells includes the steps of identifying tumor tissue from collected tissue containing tumor tissue and non-tumor tissue, allowing the immune cells to act on the tumor tissue, identifying the distribution of immune cells in the tumor tissue, and detecting the degree of accumulation of immune cells in the tumor tissue, and determining that the immune cells have acquired immunity if the degree of accumulation is equal to or greater than a reference value.

The invention discloses brown cattle bone marrow collagen polypeptide with an immunoregulation effect as well as a preparation method and application of the brown cattle bone marrow collagen polypeptide, and belongs to the technical field of animal-derived food processing. The preparation method comprises the following steps: pretreating brown cattle bone marrow; the method comprises the following steps: dissolving pretreated brown cattle bone marrow in water, firstly adding alkaline protease to carry out enzymolysis, then simultaneously adding collagenase U and basophilic protease into a system, carrying out coupled enzymolysis under the protection of nitrogen, then cooling the system to 0-4 DEG C, regulating the pH value to 3-4, then carrying out autolysis for 10-30 minutes, and finally carrying out enzyme deactivation; centrifuging an enzyme deactivation product, taking supernatant, adjusting the pH value to be neutral, concentrating, dialyzing and freeze-drying to obtain crude collagen peptide; and carrying out primary purification and secondary refining on the crude collagen peptide to obtain the collagen peptide. The preparation process is simple, the molecular weight of the prepared polypeptide is 366-1514 Da, and the polypeptide has immunoregulation and antioxidant activity, can be used for preparing food, health care products or medicines for improving immunity and resisting oxidation, and realizes high-value utilization of livestock and poultry byproducts.

The invention belongs to the technical field of biological medicine and health food, and provides a composition for preventing and improving sarcopenia and immunity decline caused by cancers and related treatment as well as a preparation method and application of the composition. The composition comprises the following components: nucleotide, beta-hydroxy beta-methyl butyrate, arginine, histidine, glutathione, fish oil, algal oil and vitamin E. The composition has a remarkable effect on improving sarcopenia and immunity decline caused by cancers and related treatment under the compounding of the components.

Disclosed herein is a method of providing an anti-cancer immunity in a subject with a bone metastatic cancer. The method involves co-administering to the subject an effective amount of a gamma-delta T cell stimulating agent and an effective amount of a γδ CAR T cell that binds a tumor antigen. Also disclosed herein is a recombinant T cell that expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR) polypeptide.

Disclosed herein is a small molecule targeted drug conjugate for anti-influenza chemotherapy and immunotherapy. The disclosed drug conjugate may form an adaptor to recruit additional CAR T cells or other immune cells for precise elimination of influenza virus-infected cells in a subject. Concurrently administered antibodies or pre-existing immunity in influenza-virus infected subject works well with the targeted conjugate to eliminate virus infected cells, saving valuable time for rescuing late stage patients.

The present invention relates to a WKYMVm peptide analogue and uses thereof, and the WKYMVm peptide analogues have increased stability due to an increased in vivo degradation half-life, enhance activity of neutrophils as a formylpeptide receptor agonist, and regulate the activity of immune cells mediating pathology of multiple sclerosis so that they can be effectively used for enhancing immunity or preventing or treating multiple sclerosis.

This invention provides an application of a nutritional composition for enhancing immunity. The nutritional composition of this invention comprises medium- and long-chain triglycerides (MLCT) and milk fat globule membrane (MFGM) in a mass ratio of 0.3:1 to 120:1. This nutritional composition can increase the proliferation of immune cells, and is used as a method for improving immunity.

This invention discloses a sialyl polysaccharide-sialic acid-binding immunoglobulin-like lectin signaling pathway blocker, containing one or more N-acetylneuraminic acid derivatives, used to manufacture immunotherapy synergistic drugs or immunomodulatory drugs. The immunotherapy synergistic drugs are used in combination with immunotherapy drugs, and the immunomodulatory drugs are used to enhance the regulation of immunity.

The application discloses a fusion protein ABD / Fc / IL-2, a coding gene thereof, a preparation method and application, and belongs to the field of biopharmaceuticals. The fusion protein ABD / Fc / IL-2 provided comprises a human serum albumin binding domain ABD, a full-length human immunoglobulin Fc segment and IL-2 or a mutant thereof. The fusion protein can effectively stimulate the proliferation of immune cells in the body, enhance the immunity of the body, and has high biological activity and a long plasma circulation half-life, or has high biological activity, a long plasma circulation half-life and low toxic side effects. The fusion protein can be used for preparing medicines for treating various diseases such as malignant tumors, infectious diseases and low immunity of the body, and can play an important role in the fields of medicine and biopharmaceuticals.